3/17
09:05 am
ogen
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K [Yahoo! Finance]
Medium
Report
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K [Yahoo! Finance]
3/17
08:30 am
ogen
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
Medium
Report
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K
3/13
07:48 am
ogen
PRISM BioLab partners with Receptor.AI for molecule discovery [Yahoo! Finance]
Medium
Report
PRISM BioLab partners with Receptor.AI for molecule discovery [Yahoo! Finance]
3/12
09:05 am
ogen
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION [Yahoo! Finance]
Low
Report
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION [Yahoo! Finance]
3/12
08:30 am
ogen
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
Low
Report
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION
3/11
09:00 am
ogen
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION [Yahoo! Finance]
High
Report
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION [Yahoo! Finance]
3/11
08:30 am
ogen
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
High
Report
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION
3/10
08:40 am
ogen
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia [Yahoo! Finance]
Medium
Report
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia [Yahoo! Finance]
3/10
08:30 am
ogen
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
Low
Report
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia
2/9
08:30 am
ogen
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
Medium
Report
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy
2/3
08:42 am
ogen
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program [Yahoo! Finance]
Medium
Report
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program [Yahoo! Finance]
2/3
08:30 am
ogen
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
High
Report
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
2/2
08:47 am
ogen
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care [Yahoo! Finance]
Low
Report
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care [Yahoo! Finance]
2/2
08:30 am
ogen
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
Low
Report
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care
1/14
08:30 am
ogen
Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico
Medium
Report
Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico